Literature DB >> 32516092

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Veda N Giri1,2,3, Karen E Knudsen3, William K Kelly1, Heather H Cheng4, Kathleen A Cooney5, Michael S Cookson6, William Dahut7, Scott Weissman8, Howard R Soule9, Daniel P Petrylak10, Adam P Dicker11, Saud H AlDubayan12, Amanda E Toland13, Colin C Pritchard14, Curtis A Pettaway15, Mary B Daly16, James L Mohler17, J Kellogg Parsons18, Peter R Carroll19, Robert Pilarski20, Amie Blanco21, Ashley Woodson15, Alanna Rahm22, Mary-Ellen Taplin12, Thomas J Polascik23, Brian T Helfand24, Colette Hyatt25, Alicia K Morgans26, Felix Feng27, Michael Mullane28, Jacqueline Powers29, Raoul Concepcion30, Daniel W Lin31, Richard Wender32, James Ryan Mark2, Anthony Costello33, Arthur L Burnett34, Oliver Sartor35, William B Isaacs36, Jianfeng Xu24, Jeffrey Weitzel37, Gerald L Andriole38, Himisha Beltran39, Alberto Briganti40, Lindsey Byrne41, Anne Calvaresi2, Thenappan Chandrasekar2, David Y T Chen16, Robert B Den11, Albert Dobi42, E David Crawford43, James Eastham44, Scott Eggener45, Matthew L Freedman39, Marc Garnick46, Patrick T Gomella47, Nathan Handley1, Mark D Hurwitz11, Joseph Izes2, R Jeffrey Karnes48, Costas Lallas2, Lucia Languino3, Stacy Loeb49, Ana Maria Lopez1, Kevin R Loughlin50, Grace Lu-Yao1, S Bruce Malkowicz51, Mark Mann2, Patrick Mille1, Martin M Miner52, Todd Morgan53, Jose Moreno54, Lorelei Mucci55, Ronald E Myers1, Sarah M Nielsen45, Brock O'Neil56, Wayne Pinover57, Peter Pinto47, Wendy Poage58, Ganesh V Raj59, Timothy R Rebbeck55, Charles Ryan60, Howard Sandler61, Matthew Schiewer3, E Michael D Scott62, Brittany Szymaniak63, William Tester1, Edouard J Trabulsi2, Neha Vapiwala51, Evan Y Yu64, Charnita Zeigler-Johnson1, Leonard G Gomella2.   

Abstract

PURPOSE: Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services.
METHODS: A multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework. Evidence review informed questions using the modified Delphi model. The final framework included criteria with strong (> 75%) agreement (Recommend) or moderate (50% to 74%) agreement (Consider).
RESULTS: Large germline panels and somatic testing were recommended for metastatic PCA. Reflex testing-initial testing of priority genes followed by expanded testing-was suggested for multiple scenarios. Metastatic disease or family history suggestive of hereditary PCA was recommended for GT. Additional family history and pathologic criteria garnered moderate consensus. Priority genes to test for metastatic disease treatment included BRCA2, BRCA1, and mismatch repair genes, with broader testing, such as ATM, for clinical trial eligibility. BRCA2 was recommended for active surveillance discussions. Screening starting at age 40 years or 10 years before the youngest PCA diagnosis in a family was recommended for BRCA2 carriers, with consideration in HOXB13, BRCA1, ATM, and mismatch repair carriers. Collaborative (point-of-care) evaluation models between health care and genetic providers was endorsed to address the genetic counseling shortage. The genetic evaluation framework included optimal pretest informed consent, post-test discussion, cascade testing, and technology-based approaches.
CONCLUSION: This multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era. Multiple research, education, and policy needs remain of importance.

Entities:  

Mesh:

Year:  2020        PMID: 32516092      PMCID: PMC7430215          DOI: 10.1200/JCO.20.00046

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  89 in total

1.  Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.

Authors:  Pedro Isaacsson Velho; John L Silberstein; Mark C Markowski; Jun Luo; Tamara L Lotan; William B Isaacs; Emmanuel S Antonarakis
Journal:  Prostate       Date:  2018-01-25       Impact factor: 4.104

2.  Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Chao Liang; Hao Wang; Yan Chen; John L Silberstein; Danilo Piana; Zhao Lai; Yidong Chen; William B Isaacs; Jun Luo
Journal:  Eur Urol       Date:  2018-02-10       Impact factor: 20.096

3.  A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.

Authors:  Yishuo Wu; Hongjie Yu; S Lilly Zheng; Rong Na; Mufaddal Mamawala; Tricia Landis; Kathleen Wiley; Jacqueline Petkewicz; Sameep Shah; Zhuqing Shi; Kristian Novakovic; Michael McGuire; Charles B Brendler; Qiang Ding; Brian T Helfand; H Ballentine Carter; Kathleen A Cooney; William B Isaacs; Jianfeng Xu
Journal:  Prostate       Date:  2018-03-09       Impact factor: 4.104

4.  Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors.

Authors:  Bronson D Riley; Julie O Culver; Cécile Skrzynia; Leigha A Senter; June A Peters; Josephine W Costalas; Faith Callif-Daley; Sherry C Grumet; Katherine S Hunt; Rebecca S Nagy; Wendy C McKinnon; Nancie M Petrucelli; Robin L Bennett; Angela M Trepanier
Journal:  J Genet Couns       Date:  2011-12-02       Impact factor: 2.537

5.  Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.

Authors:  S M Edwards; D G R Evans; Q Hope; A R Norman; Y Barbachano; S Bullock; Z Kote-Jarai; J Meitz; A Falconer; P Osin; C Fisher; M Guy; S G Jhavar; A L Hall; L T O'Brien; B N Gehr-Swain; R A Wilkinson; M S Forrest; D P Dearnaley; A T Ardern-Jones; E C Page; D F Easton; R A Eeles
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

6.  Introduction to the 2019 Philadelphia Prostate Cancer Consensus Program: 'Implementation of Genetic Testing for Inherited Prostate Cancer'.

Authors:  Leonard G Gomella; Karen E Knudsen; Veda N Giri
Journal:  Can J Urol       Date:  2019-10       Impact factor: 1.344

7.  African American and Asian males: what do we know about germline predisposition to prostate cancer.

Authors:  Curtis A Pettaway
Journal:  Can J Urol       Date:  2019-10       Impact factor: 1.344

8.  Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.

Authors:  Piper Nicolosi; Elisa Ledet; Shan Yang; Scott Michalski; Brandy Freschi; Erin O'Leary; Edward D Esplin; Robert L Nussbaum; Oliver Sartor
Journal:  JAMA Oncol       Date:  2019-04-01       Impact factor: 31.777

9.  Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.

Authors:  Elizabeth C Page; Elizabeth K Bancroft; Mark N Brook; Melissa Assel; Mona Hassan Al Battat; Sarah Thomas; Natalie Taylor; Anthony Chamberlain; Jennifer Pope; Holly Ni Raghallaigh; D Gareth Evans; Jeanette Rothwell; Lovise Maehle; Eli Marie Grindedal; Paul James; Lyon Mascarenhas; Joanne McKinley; Lucy Side; Tessy Thomas; Christi van Asperen; Hans Vasen; Lambertus A Kiemeney; Janneke Ringelberg; Thomas Dyrsø Jensen; Palle J S Osther; Brian T Helfand; Elena Genova; Rogier A Oldenburg; Cezary Cybulski; Dominika Wokolorczyk; Kai-Ren Ong; Camilla Huber; Jimmy Lam; Louise Taylor; Monica Salinas; Lidia Feliubadaló; Jan C Oosterwijk; Wendy van Zelst-Stams; Jackie Cook; Derek J Rosario; Susan Domchek; Jacquelyn Powers; Saundra Buys; Karen O'Toole; Margreet G E M Ausems; Rita K Schmutzler; Kerstin Rhiem; Louise Izatt; Vishakha Tripathi; Manuel R Teixeira; Marta Cardoso; William D Foulkes; Armen Aprikian; Heleen van Randeraad; Rosemarie Davidson; Mark Longmuir; Mariëlle W G Ruijs; Apollonia T J M Helderman van den Enden; Muriel Adank; Rachel Williams; Lesley Andrews; Declan G Murphy; Dorothy Halliday; Lisa Walker; Annelie Liljegren; Stefan Carlsson; Ashraf Azzabi; Irene Jobson; Catherine Morton; Kylie Shackleton; Katie Snape; Helen Hanson; Marion Harris; Marc Tischkowitz; Amy Taylor; Judy Kirk; Rachel Susman; Rakefet Chen-Shtoyerman; Allan Spigelman; Nicholas Pachter; Munaza Ahmed; Teresa Ramon Y Cajal; Janez Zgajnar; Carole Brewer; Neus Gadea; Angela F Brady; Theo van Os; David Gallagher; Oskar Johannsson; Alan Donaldson; Julian Barwell; Nicola Nicolai; Eitan Friedman; Elias Obeid; Lynn Greenhalgh; Vedang Murthy; Lucia Copakova; Sibel Saya; John McGrath; Peter Cooke; Karina Rønlund; Kate Richardson; Alex Henderson; Soo H Teo; Banu Arun; Karin Kast; Alexander Dias; Neil K Aaronson; Audrey Ardern-Jones; Chris H Bangma; Elena Castro; David Dearnaley; Diana M Eccles; Karen Tricker; Jorunn Eyfjord; Alison Falconer; Christopher Foster; Henrik Gronberg; Freddie C Hamdy; Vigdis Stefansdottir; Vincent Khoo; Geoffrey J Lindeman; Jan Lubinski; Karol Axcrona; Christos Mikropoulos; Anita Mitra; Clare Moynihan; Gadi Rennert; Mohnish Suri; Penny Wilson; Tim Dudderidge; Judith Offman; Zsofia Kote-Jarai; Andrew Vickers; Hans Lilja; Rosalind A Eeles
Journal:  Eur Urol       Date:  2019-09-16       Impact factor: 20.096

10.  Inherited NBN Mutations and Prostate Cancer Risk and Survival.

Authors:  Bogna Rusak; Wojciech Kluźniak; Dominika Wokołorczykv; Klaudia Stempa; Aniruddh Kashyap; Jacek Gronwald; Tomasz Huzarski; Tadeusz Dębniak; Anna Jakubowska; Bartłomiej Masojć; Mohammad R Akbari; Steven A Narodv; Jan Lubiński; Cezary Cybulski
Journal:  Cancer Res Treat       Date:  2018-12-13       Impact factor: 4.679

View more
  50 in total

1.  Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment.

Authors:  Bradley Carthon; Hannah C Sibold; Shannon Blee; Rebecca D Pentz
Journal:  Oncologist       Date:  2021-03-22

2.  Diagnostic value of retrospectively fused 64CuCl2 PET/MRI in biochemical relapse of prostate cancer: comparison with fused 18F-Choline PET/MRI, 64CuCl2 PET/CT, 18F-Choline PET/CT, and mpMRI.

Authors:  Francesco Paparo; Alice Peirano; João Matos; Lorenzo Bacigalupo; Umberto Rossi; Ilaria Mussetto; Gianluca Bottoni; Martina Ugolini; Carlo Introini; Filippo Grillo Ruggieri; Gian Andrea Rollandi; Arnoldo Piccardo
Journal:  Abdom Radiol (NY)       Date:  2020-11

3.  Using a Genomics Taxonomy: Facilitating Patient Care Safety and Quality in the Era of Precision Oncology.

Authors:  Patricia Friend; Erin Dickman; Kathleen Calzone
Journal:  Clin J Oncol Nurs       Date:  2021-04-01       Impact factor: 1.027

Review 4.  [Intelligent early prostate cancer detection in 2021: more benefit than harm].

Authors:  N Westhoff; J von Hardenberg; M-S Michel
Journal:  Urologe A       Date:  2021-04-21       Impact factor: 0.639

Review 5.  Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.

Authors:  Brittany M Szymaniak; Lauren A Facchini; Veda N Giri; Emmanuel S Antonarakis; Tomasz M Beer; Maria I Carlo; Daniel C Danila; Mallika Dhawan; Daniel George; Julie N Graff; Shilpa Gupta; Elisabeth Heath; Celestia S Higano; Glenn Liu; Ana M Molina; Channing J Paller; Akash Patnaik; Daniel P Petrylak; Zachery Reichert; Matthew B Rettig; Charles J Ryan; Mary-Ellen Taplin; Jake Vinson; Young E Whang; Alicia K Morgans; Heather H Cheng; Rana R McKay
Journal:  JCO Oncol Pract       Date:  2020-09-28

Review 6.  Molecular tracing of prostate cancer lethality.

Authors:  Yuanshuo Alice Wang; John Sfakianos; Ashutosh K Tewari; Carlos Cordon-Cardo; Natasha Kyprianou
Journal:  Oncogene       Date:  2020-10-12       Impact factor: 9.867

7.  Findings from a Genetic Sequencing Investigation of Men with Familial and Aggressive Prostate Cancer.

Authors:  Burcu F Darst
Journal:  Eur Urol       Date:  2020-09-29       Impact factor: 20.096

Review 8.  Prostate cancer.

Authors:  Richard J Rebello; Christoph Oing; Karen E Knudsen; Stacy Loeb; David C Johnson; Robert E Reiter; Silke Gillessen; Theodorus Van der Kwast; Robert G Bristow
Journal:  Nat Rev Dis Primers       Date:  2021-02-04       Impact factor: 52.329

9.  Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement.

Authors:  Gennady Bratslavsky; Neil Mendhiratta; Michael Daneshvar; James Brugarolas; Mark W Ball; Adam Metwalli; Katherine L Nathanson; Phillip M Pierorazio; Ronald S Boris; Eric A Singer; Maria I Carlo; Mary B Daly; Elizabeth P Henske; Colette Hyatt; Lindsay Middleton; Gloria Morris; Anhyo Jeong; Vivek Narayan; W Kimryn Rathmell; Ulka Vaishampayan; Bruce H Lee; Dena Battle; Michael J Hall; Khaled Hafez; Michael A S Jewett; Christina Karamboulas; Sumanta K Pal; A Ari Hakimi; Alexander Kutikov; Othon Iliopoulos; W Marston Linehan; Eric Jonasch; Ramaprasad Srinivasan; Brian Shuch
Journal:  Cancer       Date:  2021-08-03       Impact factor: 6.860

10.  Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion.

Authors:  Samantha E Greenberg; Trevor C Hunt; Jacob P Ambrose; William T Lowrance; Christopher B Dechet; Brock B O'Neil; Jonathan D Tward
Journal:  JCO Precis Oncol       Date:  2021-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.